News and Announcements
Prescient Therapeutics Ltd FY15 Company Update
- Published February 03, 2015 2:40PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Prescient Therapeutics (ASX:PTX), is a clinical stage oncology company developing small molecule inhibitors of the Ras and AKT signalling pathways to treat a range of cancers of unmet medical need, including breast, multiple myeloma, ovarian and AML. Prescient has added 3 new high profile Non-Executive Director’s Mr Steve Engle, Dr James Campbell and Mr Steven Yatomi-Clarke as well as bolstering it’s Scientific Advisory Board with the addition of Professor Douglas Joshua, a world-leading expert in multiple myeloma.
Prescient has also acquired oncology company, Aktivate Therapeutics finalised on 28 November 2014, a strategic move that deepens the pipeline of exciting products that the company is advancing through the clinic. With a strengthened pipeline and management team, the company has now decided to change name and rebrand as Prescient Therapeutics.
Please click on the ‘Receive Information’ button below for more information or to register your interest.
ABOUT PRESCIENT THERAPEUTICS
Prescient Therapeutics (formerly Virax Holdings) is a clinical stage oncology company developing novel targeted approaches to treat cancers of high unmet need, such as advanced breast, ovarian, multiple myeloma and acute leukemia.
The company raised A$3M in June 2014 and has in the last 6-months acquired a deep pipeline of products through strategic company acquisitions. Prescients’ pipeline includes a small molecule inhibitor PTX-100 (GGTI 2418), capable of blocking the Ras cancer pathway as well as PTX-200 (TCN-P) which inhibits the AKT pathway, another key pathway that contributes to cancer.
Together these novel drugs provide Prescient the unique ability to run five active clinical trials, within the next 12-months, at some of the worlds best Cancer Centers. The aim is to bring to provide better outcomes for cancer patients around the world.